Abstract Purpose: Genetic polymorphisms in genes encoding for enzymes involved in the biotransformation of carcinogens have been shown to be relevant as risk for cancer and may be of considerable importance from a public health point of view. Considering that N-acetyltransferase 2 (NAT2) polymorphisms modulate the response to ionizing radiation, the strongest risk factor recognized to cause differentiated thyroid cancer (DTC) thus far, we sought to determine the influence of NAT2 detoxification system on thyroid cancer susceptibility. Experimental Design:We conducted a prospective case-control study, comparing195 patients presenting with DTC that were previously genotyped for GSTT1, GSTM1, GSTP1, and CYP1A1, comprising 164 papillary carcinomas and 31 follicular carcinomas, with 196 control individuals paired for gender, age, ethnicity, diet routine, lifetime occupational history, smoking history, general health conditions, and previous diseases.We used PCR-RFLP assays and the combination of 6 variant alleles to define 18 NAT2 haplotypes that characterized slow, intermediate, or rapid phenotypes. Results: A multivariate logistic regression analysis identified the presence of *12A and the absence of *12B, *13, *14B, *14D, *6A, and *7A NAT2 haplotypes as risk factors for DTC. The inheritance of a rapid acetylation phenotype doubled the risk for a papillary carcinoma (odds ratio, 2.024; 95% confidence interval, 1.252-3.272).We found no relationship between genotypes and clinical, pathologic, or laboratory features of patients or between genotypes and outcome. Conclusions: We showed that NAT2 genotypes and the NAT2 rapid acetylation phenotype are important susceptibility factors for DTC, suggesting that NAT2 detoxification system is involved in this tumor pathogenesis.
Thyroid cancer is the type of human cancer that has the highest increase in incidence rate in the United States (1) . 1 Brazilian data confirm the increase of Brazilian number of cases as well, especially among women (2) . 2 This greater incidence may be due to better, high-technology diagnostic tests, which are detecting very small tumors, most of which pose no long-term threat (1) . However, a real increase, perhaps caused by environmental factors, cannot be ruled out.
Epidemiologic studies have shown that a significant part of all cancers are related to environmental factors, considering tobacco smoke and diet as the main attributable exposures in a long and increasing list of carcinogenic elements (3) . However, most carcinogens do not produce their biological effects per se; they require metabolic activation before they can interact with cellular macromolecules (4) . Many compounds are converted to reactive electrophilic metabolites by oxidative (phase I) enzymes such as cytochrome P450 (CYP) enzymes, which presumably mostly activate the majority of carcinogens. Conversely, phase II enzymes usually act as inactivating enzymes catalyzing the conjugations of carcinogenic substance. Phase II group of enzymes includes glutathione S-transferase (GST), UDP-glucuronosyltransferase, and N-acetyltransferase (NAT) systems (5) .
Arylamine NAT2 is predominantly expressed in the liver. The enzyme is responsible for the N-acetylation of arylamine and hydrazine xenobiotics and has been implicated in the susceptibility to various cancers and other disorders (6 -10) . The wild-type NAT2*4 allele (haplotype) and 35 other variants of NAT2 encoding gene were identified and classified in human populations depending on the haplotype determined by the combination of up to 4 of the 17 different single nucleotide polymorphisms (SNP) present throughout the NAT2 coding region (11) . 3 Several nonsynonymous polymorphisms result in poor expression, an unstable protein, or decreased catalytic activity (12) . According to functional studies, NAT2 polymorphisms generate slow, intermediate, and rapid acetylators (11, 13) . Association between slow NAT2 acetylator genotypes and increased risk for urinary bladder cancer as well as between rapid NAT2 acetylator genotypes and colorectal cancer have been consistently reported (9, 14) . Genes encoding metabolizing enzyme variants important in the metabolism and biotransformation of toxic xenobiotics and endobiotics have been frequently associated with the risk for cancer. An increase in the susceptibility to thyroid cancer was reported in individuals with GSTT1 and GSTM1 null genes, GSTP1, codon 72 of TP53 and CYP1A1 variants, among other components of the detoxifying system inherited genetic profile (15 -17) . NAT2 polymorphisms modulate the response to ionizing radiation, which is the strongest risk factor known for the development of differentiated thyroid cancer (DTC) thus far (18, 19) . However, reports on the role of the NAT2 detoxification system in thyroid cancer susceptibility are still scarce in the literature (20, 21) . Hence, the aim of this study was to determine the influence of NAT2 inherited genetic and phenotypic profiles on thyroid cancer susceptibility in the Brazilian population.
Materials and Methods
This prospective case-control study was approved by the Ethics Research Committee of the Faculty of Medical Sciences School, State University of Campinas, and all individuals signed informed written consent forms.
Patients. One hundred ninety-five patients presenting with differentiated thyroid carcinomas that were previously genotyped for GSTT1, GSTM1, GSTP1, and CYP1A1 were selected from the patients consecutively referred to our Teaching Hospital (Faculty of Medical Sciences School, State University of Campinas) for thyroid nodule evaluation from year 1999 to 2008. The tumor stage and grade of differentiation were obtained from surgical and pathologic records. Experienced pathologists from the Teaching Hospital confirmed all diagnoses. There were 164 papillary carcinomas and 31 follicular carcinomas. All patients were submitted to total or neartotal thyroidectomy. Patients with preoperatively or intraoperatively palpable neck node metastases underwent regional neck dissection. Four to 6 weeks after the surgeries, total body 131 I scans were done. All patients received 100 mCi 131 I. Long-term levothyroxine at suppressive doses was administered following total body scan to maintain serum thyrotropin at low normal levels.
Data regarding lifetime occupational history, dietary habits, alcohol, coffee and drug consumption, medical history with an emphasis on previous and/or current thyroid diseases, use of exogenous hormones and concomitant medications, reproductive history, and family history of cancer and other anamnestic data were obtained during interviews using a structured questionnaire. Individuals with history of previous thyroid disease, accidental or medical radiation exposure, and antecedents of other malignancies were excluded. Ethnicity was determined by the interviewer in accordance with the Brazilian Institute of Geography and Statistics; however, due to the difficulty in classifying our highly heterogeneous population, we further grouped individuals into Whites and non-Whites. 2 The habit of cigarette smoking was recorded; however, due to the limited reliable data obtained as to the duration in years of smoking, at what age smoking started, quantity smoked, and number of years since smoking stopped, the patients were grouped into the categories neversmoked and ever-smoked. This last group included comprised individuals who consumed at least 20 packages, 20 cigarettes per pack during 1 year for the prior 5 years. All data, including nodule size, tumor histologic features, and laboratory examinations, were confirmed in the patients' records.
Follow-up. Cancer patients were followed with periodic total body scans and serum thyrotropin and thyroglobulin measurements according to a routine follow-up protocol that included X-ray, ultrasonography, computed tomography scan, and other eventual procedures to detect distant metastasis for a period of 12 to 341 months (38 F 69 months). Patients with high serum thyroglobulin levels (>2 mg/dL) and/or suspicious total body scans were submitted to a thorough image search. We defined tumors as recurrent and/or presenting long distance metastasis according to the above variables.
Controls. We used DNA and anamnestic data of 196 individuals selected from the general population of our region, considered to have a normal iodine intake, who had been previously genotyped for GSTT1, GSTM1, GSTP1, NAT2 , and CYP1A1 in our laboratory. These individuals were matched based on genotypes, age, diet routine including coffee and consumption of well-done meat, lifetime occupational history, smoking history, general health conditions, and previous diseases. Individuals with a history of past thyroid disease, radiation exposure, specific environment or risk occupational exposure risks, and antecedents of malignancy were excluded.
Identification of genotypes, haplotypes, and phenotypes. Blood specimens were obtained from all patients and control individuals. Genomic DNA was extracted from frozen specimens and leukocytes were separated from whole blood using a standard phenol-chloroform protocol. Genotyping was conducted with blinding to case/control status. We used a PCR-RFLP assay to investigate 6 SNP sites in the NAT2 gene. Three of the polymorphisms result in an amino acid change (SNPs 191 G>A, 590 G>A, and 857 G>A) and the other three (282 C>T, 481 C>T, and 803 A>T) are silent mutations. Two sets of primers were used for PCR amplification: NAT2 forward1 5 ¶-CATGGAGTTGGGCT-TAGAGGC-3 ¶ and reverse1 5 ¶-ACTGCTCTCTCCTGATTTGGTCC-3 ¶ and NAT2 forward2 5 ¶-ATCAGCCTCAGGTGCCTTGC-3 ¶ and reverse2 5 ¶-GA-GTTGGGTGATACATACACAAGGG 3 ¶, which produce a 364 and 491 bp fragments, respectively. These fragments were amplified separately, although under similar conditions, using 50 AL volumes of a mixture containing 100 ng DNA, 10 AL of each primer, 10 mmol/L Tris-HCl (pH 8.0), 0.1 mmol/L of each deoxynucleotriphosphates, 2.0 mmol/L MgCl 2 , and 0.5 units Taq DNA polymerase. PCR conditions were carried out for 35 cycles at 94jC for 50 s, annealing temperatures at
Translational Relevance
Thyroid nodules are very frequent among the general population in contrast to thyroid cancer. Recognition of those individuals who are at an increased risk for cancer is important for planning and implementing proper prevention and management strategies. Although diagnostic tools such as ultrasonography and fine-needle aspiration cytology are very useful, these procedures are not appropriate to screen large populations for malignancy. Conversely, the identification of molecular markers such as high-frequency genetic polymorphisms could be applied to a great number of individuals and conceivably identify persons at risk for cancer among the vast majority presenting benign nodules. In an effort to delineate polygenic models of thyroid cancer susceptibility and prognosis, we showed that NAT2 system is an independent factor of susceptibility. We suggest that, together with other markers, NAT2 polymorphisms may help delineate a polygenic model of DTC risk among the large population of individuals with thyroid nodules. 60jC for 45 s for NAT2FR1 and at 61jC for NAT2FR2 followed by 72jC for 1 min, with an initial denaturation step at 94jC for 5 min and a final extension step at 72jC for 10 min, using a Thermocycler MJ PTC-200 PCR System. After amplification, the fragments were digested with KpnI (T481C), BamHI (G857A), DdeI (A803G; Invitrogen/Life Technologies), and HpaII (G191A) for 16 h at 37jC (Fermentas Life Sciences, EU); TaqI (G590A; Invitrogen/Life Technologies) for 16 h at 65jC; and BseGI (C282T; Fermentas Life Sciences, EU) for 16 h at 55jC separately in a 15 AL final volume. The six variant alleles investigated resulted in 18 (*5D, *6A, *6B, *6C, *6E, *7A, *7B, *11A, *12A, *12B, *12C, *13, *14A, *14B, *14C, *14D, *14E, and *14G) different haplotypes according to the current nomenclature. 3 We used the scheme suggested by Vatsis et al. to classify new NAT identified alleles (11) . Individuals homozygous for rapid NAT2 acetylator alleles (NAT2 *4, NAT2 *11A, NAT2*12A, NAT2 *12B, NAT2*12C, and NAT2*13A) were classified as rapid acetylator phenotype; individuals homozygous for slow acetylator alleles were classified as slow acetylator phenotype and heterozygous individuals (one rapid and one slow NAT2 allele) were classified as intermediate acetylator phenotype.
GSTT1, GSTM1, GSTP1, and CYP1A1(m2) genotyping methods have been described previously in other publications (15 -17) .
Statistical analysis. The statistical analysis was carried out using SAS statistical software (Statistical Analysis System, version 8.1, 1999-2000) . Associations were assessed using contingency table analysis, and the m 2 or Fisher's exact test was used to examine the homogeneity between cases and controls regarding gender, ethnicity, previous thyroid disease, thyroid nodule size, medication use, cigarette smoking, disease extent, and genotypes. The Mann-Whitney or Wilcoxon tests were used to compare the age among two or more than two different genotype groups, respectively.
Logistic regression was used to evaluate the effect of all genotypes after adjusting for other potential confounders such as CYP1A1(m1) genotype, age, ethnicity, gender, and tobacco, alcohol, and medication consumption. A multivariate logistic regression model was applied using type of tumor (papillary or follicular carcinoma) as dependent variables and all genotypes and clinical risk factors, including gender, ethnicity, age, cigarette smoking, and coffee drinking as explicative variables. Study power, the likelihood of detecting an association when one exists, was calculated using PS power and sample size calculation program version 2.1.31. All tests were conducted at the significance level P = 0.05.
Because we evaluated associations with multiple SNPs and haplotypes, some associations would appear by chance. To correct for multiple comparisons, we calculated the false-positive report probability (FPRP) for all associations observed to be statistically significant in the overall analysis or which seemed to differ within subgroups in the stratified analyses (22, 23) . The FPRP were computed by the Excel spreadsheet provided by Wacholder et al. and represent the probability that the observed association is a false-positive result. The FPRP depends on the observed result, the prior probability of an association, and the power of calculation of the study. The calculations further assume that the power is to detect, under the dominant model, an odds ratio (OR) of 2.0 for both SNPs and haplotypes, considering prior probabilities for association with thyroid cancer according to the values calculated by the software to be noteworthy for each SNP and haplotype. We considered FPRP < 0.200 to indicate a noteworthy association. 4 Results Table 1 summarizes clinical characteristics, variables of aggressiveness at diagnosis and during follow-up of the thyroid cancer patients divided into smokers and nonsmokers, and some of the genotypes analyzed. There were no differences between the control individuals and the thyroid disease patients regarding age, ethnicity, and cigarette smoking habits. The demographic and lifestyle characteristics of the subjects in both thyroid cancer and control groups, including coffee and alcohol consumption, red meat, vegetable, and fat intake, education level, and exercise practice, were similar. As we aimed to identify the effect of NAT2 genotypes in thyroid cancer susceptibility, patients and controls were paired for GSTT1, GSTM1, GSTP1, and CYP1A1(m2), and their profile was similar 4 http://jncicancerspectrum.oupjournals.org/jnci/content/vol96/issue6 Table 2 . However, we were not able to organize a group of patients and controls paired for all genetic and environmental exposure risks large enough to guarantee the power of calculation and avoid CYP1A1(m1) disparity between the groups. Therefore, CYP1A1(m1) was considered a confounder in the adjusted logistic regression analysis. Table 3 represents our results regarding the six NAT2 allelic polymorphisms investigated and their corresponding genotypes. We observed that NAT2C282T and NAT2G191A variants were more frequent among controls than patients. Indeed, the absence of these variants increased the risk of CDT by 6.68 and 4.60 times, respectively. The power of calculation for these variants was 99.99% (C282T) and 99.97% (G191A) and the FPRP had values <0.2 across the prespecified prior probability of 0.1 (Table 6 ). These two variant-cancer associations remained noteworthy (FPRP < 0.2). On the contrary, NAT2A803G variants were more frequent among the patients increasing the risk of CDT 1.88 times. Unfortunately, the power of calculation for this variant was only 29.92%. The analysis of the 18 haplotypes resulting from the six allelic variants investigated showed that *11A, *12B, *13, *14B, *14D, *6A, and *7A haplotypes were more frequent among controls than cancer patients, whereas *12A, *4, and *6E predominated among cancer patients as depicted in Table 4 . A multivariate logistic regression analysis confirmed the presence of *12A and the absence of *12B, *13, *14B, *14D, *6A, and *7A as significant risk factors for thyroid cancer. The power of calculation for these haplotypes was 99% (*12A), 64% (12B), 93% (*13), 64% (*14B), 81% (*14D), 62% (*6A), and 64% (*7A). FPRP calculation showed that NAT2 haplotypes *11A, *12A, *13, *6A, and *6E associations were noteworthy as shown in Table 6 . Table 5 describes the acetylation pattern of both control and case groups evidencing that a rapid acetylation is a risk factor for thyroid cancer. This effect is due to the papillary type, as follicular carcinomas do not present a significant association between acetylation and risk for cancer. Indeed, the risk of an individual presenting a rapid acetylation to develop a papillary thyroid cancer is increased more than two times [OR, 2.024; 95% confidence interval (95% CI), 1.252-3.272]. The power of calculation for this analysis is 58% for the rapid, 51% for the intermediate, and 30% for the slow acetylation phenotypes. Table 6 shows FPRP estimates for selected results. In the analyses including all thyroid cancer cases and controls, the protective effect of C282T and G191A genotypes appear to be a true result, because the association of these genotypes with thyroid cancer yielded a FPRP < 0.2. The presence of *12A and the absence of *13 and *14B haplotypes are also unlike to represent a false-positive result of factors associated to the susceptibility for thyroid cancer.
We were unable to establish any relationship between the profile of the studied genes and patients' clinical characteristics, including smoking, dietary, and coffee drinking habits. A sample size calculation indicated that a much larger cohort of patients would be needed to reach the statistical power to detect main effects or interactions or the precision to quantify them.
In addition, we were unable to find any additive or combined effects of the genes studied for thyroid cancer risk, including NAT2 and the previously examined GSTT1, GSTM1, GSTP1, and CYP1A1 genes.
As described in our previous publications on the same cases, we were once more unable to establish any relationship between the genotypes investigated and the pathologic features of the tumors or the patients' outcome.
Discussion
Tobacco products provide a clear example of cancer causation due to a lifestyle factor involving carcinogen exposure. Most tobacco carcinogens require metabolic activation to exert their carcinogenic effects; there are competing detoxification pathways and the balance between metabolic activation and detoxification differs among individuals and cancer risk (24) . Identifying a risk profile for thyroid cancer may help delineate polygenic models of cancer susceptibility and prognosis. Such models are particularly interesting, considering the elevated prevalence of thyroid nodules in the population, and may help select individuals for specific preventive interventions and determine which patients would have a greater chance to benefit from specific measures.
Taking advantage of the high admixture of the Brazilian population that represents a unique model in which the types and frequency of genetic polymorphisms of GST, CYP, and NAT enzymes are less influenced by ethnicity, we showed that NAT2 gene inheritance influences thyroid cancer susceptibility.
NAT2 polymorphisms have been shown to modulate the response to ionizing radiation, which is the strongest environmental factor proven to cause thyroid cancer thus far (25, 26) . NAT2*7 allele and the presence of slow acetylator phenotype were related to a lower increase of the micronuclei frequency detected in peripheral blood lymphocytes of patients submitted to radioiodine treatment for thyroid cancer, indicating that they could represent a protection against radiation-induced cellular damage (21) . Our data corroborate the observations made by Hernández et al., suggesting that a rapid acetylator phenotype and some NAT2 haplotypes may represent risk factors for thyroid cancer (21) . The inheritance of some variants such as NAT2*7A is protective, whereas others such as NAT2*12A increase the risk, especially for papillary carcinomas. These data also correlate very well with our recent description of an inverse association among CYP1A1 allelic variants, smoking, and thyroid cancer susceptibility (17) .
A recent study in the Saudi Arabian population found CYP1AI and GSTT1 null genes to increase the risk of thyroid cancer, whereas GSTM1 null showed a protective effect (20) . These authors included NAT2 among the 9 SNPs in 7 genes they analyzed, but the risk to develop thyroid cancer was initially assessed with only 50 samples and they selected only the SNPs that showed statistical significance to further confirm the finding with the total 223 cases they had. Hence, the power of calculation and the possibility of their results being falsepositive augmented significantly.
We suggest that the NAT2 detoxification system exerts an important role in the protection against environmental and/or endogenous factors involved in differentiated thyroid carcinomas pathogenesis. NAT2 polymorphisms represent independent factors of susceptibility that, together with other molecular markers, may help delineate a polygenic model of DTC risk among the large population of individuals with thyroid nodules. Future investigations are needed to test the capacity of this model reduce the number of patients submitted to fineneedle aspiration cytology and, consequently, the burden of the procedure and its cost.
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